PsiOxus Appoints GSK's Former Oncology President As Chair
This article was originally published in Scrip
PsiOxus Therapeutics Ltd. has appointed Paolo Paoletti chair of its board of directors. Most recently, Paoletti was president of GlaxoSmithKline (GSK) Oncology and prior to this he was vice president of clinical development for Lilly Oncology. Currently, Paoletti is CEO of Kesios Therapeutics and is on the board for Genmab A/S, FORMA Therapeutics and Nucana BioMed.